NCT06605612 - Development and Validation of the FBIndex to Determine the Risk of Falls for Patients With Neuromuscular Disorders | Biotech Hunter

Enrollment

108

Participants

Timeline

Start Date

September 9, 2024

Primary Completion Date

August 1, 2027

Study Completion Date

January 1, 2028

Conditions

Inclusion Body MyositisMyotonic DystrophyLimb-girdle and Facioscapulohumeral Muscular DystrophiesPompe DiseaseMyasthenia GravisLambert-Eaton-SyndromeAmyotrophic Lateral SclerosisSpinal Muscular AtrophyGuillain-Barré SyndromeChronic Inflammatory Demyelinating PolyneuropathyFriedreich AtaxiaHereditary Motor Sensory Neuropathy

Interventions

DIAGNOSTIC_TEST

FBIndex

There will be no intervention.

Trial Locations (1)

80336

Friedrich-Baur-Institut, Neurologische Klinik und Poliklinik, LMU Klinikum, Ludwig-Maximilians-Universität München, München